Nose Cancer Vaccine

Grid's nose cancer vaccine (against EBV) is currently in a Phase 1 clinical trial. The target market is a global opportunity of $31B USD, as validated by Merck's $922.5M and Lilly's $1.55B EBV deal. Grid is targeting Phase 2 and its strategic options.